{"success":true,"data":{"pressRelease":{"id":"116172","rtpr_id":"nGNEMplZD","ticker":"FOCL","exchange":"NASDAQ","all_tickers":["FOCL"],"title":"FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares","author":"Globe Newswire","published_at":"2026-08-12T01:10:03.191Z","article_body":"FocalTherics™ Announces Pricing of Public Offering of American Depositary\nShares\n\nAUSTIN, Texas and LYON, France, Aug. 11, 2026 (GLOBE NEWSWIRE) --\nFocalTherics™ (NASDAQ: FOCL) (the “Company”), a global leader in robotic\nenergy-based therapies, announced the pricing of its underwritten public\noffering of 8,425,000 of American Depositary Shares (“ADSs”), each\nrepresenting one ordinary share of the Company, €0.13 nominal value per\nshare at a public offering price of $4.75 per ADS, before underwriting\ndiscounts and commissions (the “Offering”). All of the ADSs are being sold\nby the Company. In addition, the underwriters have been granted a 30-day\noption to purchase up to an additional 1,263,750 ADSs at the public offering\nprice, less underwriting discounts and commissions.  The gross proceeds from\nthe Offering, before deducting underwriting discounts and commissions and\nother offering expenses payable by the Company, are expected to be\napproximately $40.0 million. The closing of the Offering is expected to occur\non August 14, 2026, subject to customary closing conditions.\n\nTD Cowen and Mizuho are acting as joint book-running managers for the\nOffering. H.C. Wainwright & Co. and Lucid Capital Markets are acting as\nco-managers for the Offering.\n\nThe Offering is being made pursuant to a shelf registration statement on Form\nS-3 (File No. 333-294597), previously filed with the Securities and Exchange\nCommission (the “SEC”) on March 25, 2026, amended on March 27, 2026, and\ndeclared effective on March 31, 2026. The Offering is being made only by means\nof a written prospectus and prospectus supplement that form a part of the\nregistration statement. A preliminary prospectus supplement and accompanying\nprospectus relating to and describing the terms of the proposed Offering will\nbe filed with, and will be available on, the SEC’s website at www.sec.gov.\nCopies of the final prospectus supplement and the accompanying prospectus,\nwhen available, may also be obtained by contacting: TD Securities (USA) LLC,\nc/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New\nYork 11717, or by email at TDManualrequest@broadridge.com; Mizuho Securities\nUSA LLC, Attention: Equity Capital Markets, 1271 Avenue of the Americas, 3rd\nFloor, New York, NY 10020, by telephone (212) 205-7600, or by email:\nUS-ECM@mizuhogroup.com.\n\nThis press release shall not constitute an offer to sell or the solicitation\nof an offer to buy these securities, nor shall there be any sale of these\nsecurities in any state or jurisdiction in which such offer, solicitation or\nsale would be unlawful prior to registration or qualification under the\nsecurities laws of any such state or jurisdiction. In particular, no public\noffering of the ADSs will be made in Europe.\n\nAbout FocalTherics\nA recognized global leader in Robotic Focal Therapy, FocalTherics develops,\nmanufactures, and markets minimally invasive medical devices worldwide to\ntreat various conditions using proprietary focused ultrasound technology. The\nCompany’s flagship platform, Focal One Robotic HIFU, combines advanced\nimaging, real-time treatment planning, robotic precision, and HIFU technology\nto deliver personalized focal therapy designed to optimize clinical outcomes\nwhile preserving quality of life.\n\nForward-Looking Statements\nIn addition to historical information, this press release contains\nforward-looking statements within the meaning of applicable federal securities\nlaws, including Section 27A of the U.S. Securities Act of 1933 (the\n“Securities Act”) or Section 21E of the U.S. Securities Exchange Act of\n1934, as amended, including statements about the Company’s expectations\nregarding the Offering, including the expected timing and the Company’s\nexpectation that it will complete the Offering, which may be identified by\nwords such as “believe,” “can,” “contemplate,” “could,”\n“plan,” “intend,” “is designed to,” “may,” “might,”\n“potential,” “objective,” “target,” “project,” “predict,”\n“forecast,” “ambition,” “guideline,” “should,” “will,”\n“estimate,” “expect” and “anticipate,” or the negative of these\nand similar expressions, which reflect the Company’s views about future\nevents and financial performance. Such statements are based on management's\ncurrent expectations and are subject to a number of risks and uncertainties,\nincluding matters not yet known to the Company or not currently considered\nmaterial by the Company, and there can be no assurance that anticipated events\nwill occur or that the objectives set out will actually be achieved. Important\nfactors that could cause actual results to differ materially from the results\nanticipated in the forward-looking statements include, but are not limited to,\nuncertainties related to market conditions, those risks relating to the\nOffering and others described in the preliminary prospectus supplement, final\nprospectus supplement and in particular in the sections “Cautionary\nStatement on Forward-Looking Statements” and “Risk Factors” and those\nrisks relating to the Company’s business, which are described in the\nCompany’s filings with the SEC and in particular in the section “Risk\nFactors” in the Company's Annual Report on Form 10-K and most recent\nQuarterly Report on Form 10-Q.\n\nForward-looking statements speak only as of the date they are made. Other than\nrequired by law, the Company does not undertake any obligation to update them\nin light of new information or future developments. These forward-looking\nstatements are based upon information, assumptions and estimates available to\nthe Company as of the date of this press release, and while the Company\nbelieves such information forms a reasonable basis for such statements, such\ninformation may be limited or incomplete.\n\nInvestor Contact\nLouisa Smith\nGilmartin Group\ninvestor.relations@focalone.com","article_body_html":"","raw_payload":{"data":{"id":"nGNEMplZD","title":"FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares","author":"Globe Newswire","ticker":"FOCL","created":"2026-08-12T01:10:03.191Z","tickers":["FOCL"],"exchange":"NASDAQ","article_body":"FocalTherics™ Announces Pricing of Public Offering of American Depositary\nShares\n\nAUSTIN, Texas and LYON, France, Aug. 11, 2026 (GLOBE NEWSWIRE) --\nFocalTherics™ (NASDAQ: FOCL) (the “Company”), a global leader in robotic\nenergy-based therapies, announced the pricing of its underwritten public\noffering of 8,425,000 of American Depositary Shares (“ADSs”), each\nrepresenting one ordinary share of the Company, €0.13 nominal value per\nshare at a public offering price of $4.75 per ADS, before underwriting\ndiscounts and commissions (the “Offering”). All of the ADSs are being sold\nby the Company. In addition, the underwriters have been granted a 30-day\noption to purchase up to an additional 1,263,750 ADSs at the public offering\nprice, less underwriting discounts and commissions.  The gross proceeds from\nthe Offering, before deducting underwriting discounts and commissions and\nother offering expenses payable by the Company, are expected to be\napproximately $40.0 million. The closing of the Offering is expected to occur\non August 14, 2026, subject to customary closing conditions.\n\nTD Cowen and Mizuho are acting as joint book-running managers for the\nOffering. H.C. Wainwright & Co. and Lucid Capital Markets are acting as\nco-managers for the Offering.\n\nThe Offering is being made pursuant to a shelf registration statement on Form\nS-3 (File No. 333-294597), previously filed with the Securities and Exchange\nCommission (the “SEC”) on March 25, 2026, amended on March 27, 2026, and\ndeclared effective on March 31, 2026. The Offering is being made only by means\nof a written prospectus and prospectus supplement that form a part of the\nregistration statement. A preliminary prospectus supplement and accompanying\nprospectus relating to and describing the terms of the proposed Offering will\nbe filed with, and will be available on, the SEC’s website at www.sec.gov.\nCopies of the final prospectus supplement and the accompanying prospectus,\nwhen available, may also be obtained by contacting: TD Securities (USA) LLC,\nc/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New\nYork 11717, or by email at TDManualrequest@broadridge.com; Mizuho Securities\nUSA LLC, Attention: Equity Capital Markets, 1271 Avenue of the Americas, 3rd\nFloor, New York, NY 10020, by telephone (212) 205-7600, or by email:\nUS-ECM@mizuhogroup.com.\n\nThis press release shall not constitute an offer to sell or the solicitation\nof an offer to buy these securities, nor shall there be any sale of these\nsecurities in any state or jurisdiction in which such offer, solicitation or\nsale would be unlawful prior to registration or qualification under the\nsecurities laws of any such state or jurisdiction. In particular, no public\noffering of the ADSs will be made in Europe.\n\nAbout FocalTherics\nA recognized global leader in Robotic Focal Therapy, FocalTherics develops,\nmanufactures, and markets minimally invasive medical devices worldwide to\ntreat various conditions using proprietary focused ultrasound technology. The\nCompany’s flagship platform, Focal One Robotic HIFU, combines advanced\nimaging, real-time treatment planning, robotic precision, and HIFU technology\nto deliver personalized focal therapy designed to optimize clinical outcomes\nwhile preserving quality of life.\n\nForward-Looking Statements\nIn addition to historical information, this press release contains\nforward-looking statements within the meaning of applicable federal securities\nlaws, including Section 27A of the U.S. Securities Act of 1933 (the\n“Securities Act”) or Section 21E of the U.S. Securities Exchange Act of\n1934, as amended, including statements about the Company’s expectations\nregarding the Offering, including the expected timing and the Company’s\nexpectation that it will complete the Offering, which may be identified by\nwords such as “believe,” “can,” “contemplate,” “could,”\n“plan,” “intend,” “is designed to,” “may,” “might,”\n“potential,” “objective,” “target,” “project,” “predict,”\n“forecast,” “ambition,” “guideline,” “should,” “will,”\n“estimate,” “expect” and “anticipate,” or the negative of these\nand similar expressions, which reflect the Company’s views about future\nevents and financial performance. Such statements are based on management's\ncurrent expectations and are subject to a number of risks and uncertainties,\nincluding matters not yet known to the Company or not currently considered\nmaterial by the Company, and there can be no assurance that anticipated events\nwill occur or that the objectives set out will actually be achieved. Important\nfactors that could cause actual results to differ materially from the results\nanticipated in the forward-looking statements include, but are not limited to,\nuncertainties related to market conditions, those risks relating to the\nOffering and others described in the preliminary prospectus supplement, final\nprospectus supplement and in particular in the sections “Cautionary\nStatement on Forward-Looking Statements” and “Risk Factors” and those\nrisks relating to the Company’s business, which are described in the\nCompany’s filings with the SEC and in particular in the section “Risk\nFactors” in the Company's Annual Report on Form 10-K and most recent\nQuarterly Report on Form 10-Q.\n\nForward-looking statements speak only as of the date they are made. Other than\nrequired by law, the Company does not undertake any obligation to update them\nin light of new information or future developments. These forward-looking\nstatements are based upon information, assumptions and estimates available to\nthe Company as of the date of this press release, and while the Company\nbelieves such information forms a reasonable basis for such statements, such\ninformation may be limited or incomplete.\n\nInvestor Contact\nLouisa Smith\nGilmartin Group\ninvestor.relations@focalone.com"},"type":"article","timestamp":"2026-08-12T01:10:03.289385947Z","server_sent_at_ms":1786497003289},"received_at":"2026-08-12T01:10:03.342Z","source_url":"https://www.globenewswire.com/news-release/2026/08/12/3343326/9622/en/focaltherics-announces-pricing-of-public-offering-of-american-depositary-shares.html"},"analysis":{"id":"105167","press_release_id":"116172","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"offering","narrative":"FocalTherics priced a public offering of 8,425,000 American Depositary Shares at $4.75 per share, aiming for gross proceeds of approximately $40.0 million.\n\nThe underwriters have a 30-day option to purchase an additional 1,263,750 ADSs at the same price to cover over-allotments.\n\nTD Cowen and Mizuho are acting as joint book-running managers, with the deal expected to close on August 14, 2026.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"FocalTherics raises $40M in public offering priced at $4.75/share."},"keyFigures":{"dealValueUsd":40000000,"offeringPrice":4.75,"sharesOffered":8425000,"customDimensions":{"greenshoe_shares":1263750}},"quotedText":"","namedEntities":{"people":[{"name":"Louisa Smith","role":"Investor Contact"}],"products":["Focal One Robotic HIFU"],"companies":[{"name":"FocalTherics","ticker":"FOCL"},{"name":"TD Cowen","relationship":"joint book-running manager"},{"name":"Mizuho","relationship":"joint book-running manager"},{"name":"H.C. Wainwright & Co.","relationship":"co-manager"},{"name":"Lucid Capital Markets","relationship":"co-manager"}],"dollarAmounts":[{"amount":"$4.75","context":"public offering price per ADS"},{"amount":"$40.0 million","context":"expected gross proceeds"}]},"materialImpact":{"score":3,"reasoning":"The company is raising approximately $40 million in gross proceeds through the sale of 8.4 million shares, representing standard dilutive financing. While the prior close is not provided to assess the pricing discount, the size of the raise is material to the company's capital structure."},"tickerRelevance":{"others":[],"primary":"FOCL"},"globalImportance":25,"audienceRelevance":20,"eventTypeSecondary":["dilution"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"offering_pricing","sectorWeight":"health_care"}},"event_type":"offering","event_type_secondary":["dilution"],"sentiment":"bearish","material_impact_score":3,"narrative":"FocalTherics priced a public offering of 8,425,000 American Depositary Shares at $4.75 per share, aiming for gross proceeds of approximately $40.0 million.\n\nThe underwriters have a 30-day option to purchase an additional 1,263,750 ADSs at the same price to cover over-allotments.\n\nTD Cowen and Mizuho are acting as joint book-running managers, with the deal expected to close on August 14, 2026.","key_figures":{"dealValueUsd":40000000,"offeringPrice":4.75,"sharesOffered":8425000,"customDimensions":{"greenshoe_shares":1263750}},"named_entities":{"people":[{"name":"Louisa Smith","role":"Investor Contact"}],"products":["Focal One Robotic HIFU"],"companies":[{"name":"FocalTherics","ticker":"FOCL"},{"name":"TD Cowen","relationship":"joint book-running manager"},{"name":"Mizuho","relationship":"joint book-running manager"},{"name":"H.C. Wainwright & Co.","relationship":"co-manager"},{"name":"Lucid Capital Markets","relationship":"co-manager"}],"dollarAmounts":[{"amount":"$4.75","context":"public offering price per ADS"},{"amount":"$40.0 million","context":"expected gross proceeds"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-12T01:58:41.281Z","global_importance":25,"audience_relevance":20,"importance_components":{"tickerTier":"small-cap","eventGravity":"offering_pricing","sectorWeight":"health_care"}},"durationMs":226280,"modelName":"glm-4.7"}}